These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23636219)

  • 21. Multimodal assessment of non-specific hemostatic agents for apixaban reversal.
    Martin AC; Gouin-Thibault I; Siguret V; Mordohay A; Samama CM; Gaussem P; Le Bonniec B; Godier A
    J Thromb Haemost; 2015 Mar; 13(3):426-36. PubMed ID: 25630710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
    Martin AC; Le Bonniec B; Fischer AM; Marchand-Leroux C; Gaussem P; Samama CM; Godier A
    Int J Cardiol; 2013 Oct; 168(4):4228-33. PubMed ID: 23928345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro.
    Schultz NH; Tran HTT; Bjørnsen S; Henriksson CE; Sandset PM; Holme PA
    Res Pract Thromb Haemost; 2017 Jul; 1(1):49-56. PubMed ID: 30046673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
    Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
    Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prothrombin complex concentrates for the urgent reversal of apixaban and rivaroxaban: an Australian retrospective cohort study.
    Wallwork S; Wang Y; Chaiwatanatorn K; Cole-Sinclair M
    Intern Med J; 2023 May; 53(5):803-811. PubMed ID: 34779569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of warfarin-related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII.
    Pinner NA; Hurdle AC; Oliphant C; Reaves A; Lobo B; Sills A
    World Neurosurg; 2010 Dec; 74(6):631-5. PubMed ID: 21492631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate.
    Barco S; Whitney Cheung Y; Coppens M; Hutten BA; Meijers JC; Middeldorp S
    Br J Haematol; 2016 Jan; 172(2):255-61. PubMed ID: 26488126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
    Young G; Shafer FE; Rojas P; Seremetis S
    Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model.
    Honickel M; Maron B; van Ryn J; Braunschweig T; ten Cate H; Spronk HM; Rossaint R; Grottke O
    Thromb Haemost; 2016 Jan; 115(2):271-84. PubMed ID: 26333775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.
    Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
    Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation.
    Tanaka KA; Szlam F; Dickneite G; Levy JH
    Thromb Res; 2008; 122(1):117-23. PubMed ID: 17977586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How I treat target-specific oral anticoagulant-associated bleeding.
    Siegal DM; Garcia DA; Crowther MA
    Blood; 2014 Feb; 123(8):1152-8. PubMed ID: 24385535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bleeding and antidotes in new oral anticoagulants.
    Majeed A; Schulman S
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
    Parry TJ; Huang Z; Chen C; Connelly MA; Perzborn E; Andrade-Gordon P; Damiano BP
    Blood Coagul Fibrinolysis; 2011 Dec; 22(8):720-6. PubMed ID: 21986468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ex vivo reversal of the anticoagulant effects of edoxaban.
    Halim AB; Samama MM; Mendell J
    Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models.
    Ghosh S; Krege W; Doerr B; Mischnik M; Pragst I; Dickneite G; Herzog E
    PLoS One; 2021; 16(10):e0258192. PubMed ID: 34614035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.
    Levy JH; Moore KT; Neal MD; Schneider D; Marcsisin VS; Ariyawansa J; Weitz JI
    J Thromb Haemost; 2018 Jan; 16(1):54-64. PubMed ID: 29106076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating human blood.
    Escolar G; Arellano-Rodrigo E; Lopez-Vilchez I; Molina P; Sanchis J; Reverter JC; Carne X; Cid J; Villalta J; Tassies D; Galan AM; Diaz-Ricart M
    Circ J; 2015; 79(2):331-8. PubMed ID: 25482382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.
    Le Roux P; Pollack CV; Milan M; Schaefer A
    J Neurosurg; 2014 Aug; 121 Suppl():1-20. PubMed ID: 25081496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.
    Bonnet PO; Yoon BS; Wong WY; Boswell K; Ewenstein BM
    Haemophilia; 2009 Sep; 15(5):1083-9. PubMed ID: 19456876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.